VRDN-003

Phase 3Small molecule

VViridian Therapeutics, Inc.

VRDN-003 is one of 30 small molecule programs targeting Thyroid Eye Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid Eye DiseaseActive, not recruiting

Thyroid Eye DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Thyroid Eye Disease

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

3 2

Zolymbus

AbbVie

Approved

1 3

Restasis

TTaiwan Bio Therapeutics Inc.

Approved

1 4

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 5

Actemra

Roche

Phase 3

2 6

ENSPRYNG

Roche

Phase 3

2 7

Cosentyx

Novartis

Phase 3

1 8

TEPEZZA

HHorizon Therapeutics Ireland DAC

Phase 3

8 9

TEPEZZA

Amgen

Approved

1 10

Linsitinib

SSling Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Thyroid Eye Disease

NCT06812325

Phase 3Active, not recruiting

Thyroid Eye Disease

NCT06625411

Phase 3Active, not recruiting

Thyroid Eye Disease

NCT06625398

Clinical

Trials by Indication[1]

Thyroid Eye Disease4 trials

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

Active, not recruiting·VViridian Therapeutics, Inc.·Phase 3·NCT06625398·195 enrolled

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

Active, not recruiting·VViridian Therapeutics, Inc.·Phase 3·NCT06625411·117 enrolled

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Active, not recruiting·VViridian Therapeutics, Inc.·Phase 3·NCT06812325·321 enrolled

Show 1 more trial

A Randomized, Open-label Study Evaluating the Safety, Tolerability and Pharmacokinetics of VRDN-003 Administered Subcutaneously in Participants With Thyroid Eye Disease (TED)

Completed·VViridian Therapeutics, Inc.·Phase 3·NCT07155668·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for VRDN-003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VRDN-003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VRDN-003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Viridian Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VViridian Therapeutics, Inc.

VRDN-003

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Thyroid Eye Disease4 trials

References

Drug Info

Quick Facts

Related News